Last reviewed · How we verify
Early Dual IV Antibiotic Therapy - MRSA
Early dual IV antibiotic therapy combines two intravenous antibiotics to simultaneously target methicillin-resistant Staphylococcus aureus (MRSA) through complementary bactericidal mechanisms.
Early dual IV antibiotic therapy combines two intravenous antibiotics to simultaneously target methicillin-resistant Staphylococcus aureus (MRSA) through complementary bactericidal mechanisms. Used for Methicillin-resistant Staphylococcus aureus (MRSA) infection, severe or invasive.
At a glance
| Generic name | Early Dual IV Antibiotic Therapy - MRSA |
|---|---|
| Also known as | daptomycin, ceftaroline, rifampin |
| Sponsor | West Virginia University |
| Drug class | Antibiotic combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This clinical protocol uses two synergistic IV antibiotics (typically vancomycin and a beta-lactam or fluoroquinolone) administered early in suspected or confirmed MRSA infection to achieve rapid bacterial killing and reduce resistance development. The dual approach targets different bacterial cell wall or protein synthesis pathways, improving clinical outcomes compared to monotherapy in severe MRSA infections.
Approved indications
- Methicillin-resistant Staphylococcus aureus (MRSA) infection, severe or invasive
Common side effects
- Nephrotoxicity
- Ototoxicity
- Infusion-related reactions
- Hepatotoxicity
Key clinical trials
- Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis (PHASE4)
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: